Obsidian Therapeutics (OBX) Stock Price, News & Analysis

Company Overview

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins. The platform has been applied to cytokines, gene editors, transcription factors and other biological payloads that may be difficult to control with conventional treatment approaches.

The company has advanced programs in oncology, including OBX-115, an engineered tumor-infiltrating lymphocyte therapy designed to support T-cell activity through regulated expression of membrane-bound interleukin-15. Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company; reliable information confirming a Nasdaq listing under the symbol OBX was not available.

Key Stats

• Today's Range: $23.00 to $30.30
• 50-Day Range: N/A
• 52-Week Range: $23.00 to $49.97
• Volume: 18,352 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.00
• Consensus Rating: Buy

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OBX
• CIK: N/A
• Web: www.obsidiantx.com
• Phone: N/A
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Obsidian Therapeutics: $42.00
• High Price Target: $42.00
• Low Price Target: $42.00
• Potential Upside/Downside: +42.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A